; (2) gaps in data needed for full implementation of such subsection; (3) how the database established pursuant to subsection (a) increases Federal visibility into the pharmaceutical supply chain; (4) how Federal agencies are able to use data analytics to conduct predictive modeling of anticipated drug shortages or national security threats; and (5) the extent to which industry has cooperated in mapping the pharmaceutical supply chain. (c) Confidential commercial information The exchange of information among the Secretary of Health and Human Services and the heads of other relevant agencies for purposes of carrying out this section shall not be a violation of section 1905 of title 18, United States Code. (d) Clarification The information in the database established pursuant to subsection (a) shall not be publicly disclosed. Nothing in this subsection shall be construed to relieve the Secretary of Health and Human Services from the Secretary’s obligation to provide information to Congress.